Healthcare / BiotechnologyNasdaqCM
$15.13
+0.17 (+1.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-85.0M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$206M
P/E
N/A
•EV/EBITDA
N/A
•ROE
1456.2%
↑Gross Margin
N/A
•Debt/Equity
-0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-97.2M · FCF $-86.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Net Income | $-97.2M | $-97.2M | $-100.5M | $-93.6M | $-120.4M | $-92.9M | $-44.0M | $-34.9M | $-11.5M | $-52.1M | $-41.0M | $-52.0M | $-47.7M | $-32.7M | $-6.7M |
| EBITDA | $-103.1M | $-103.1M | $-97.9M | $-99.1M | $-86.4M | $-91.6M | $-48.9M | $-37.0M | $-12.0M | $-51.7M | $-39.5M | $-50.8M | $-49.3M | $-30.6M | $-8.9M |
| EPS | -6.20 | -6.20 | -10.00 | -21.10 | -37.80 | -39.30 | -28.10 | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||
| Debt/Equity | -0.09 | -0.09 | 0.05 | 0.05 | 0.01 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 4.92 | 4.92 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-86.0M | $-86.0M | $-85.0M | $-71.2M | $-65.3M | $-83.3M | $-46.3M | $-28.6M | $-9.8M | $-41.1M | $-36.3M | — | — | — | — |
| Returns | |||||||||||||||
| ROE | 1456.2% | 1456.2% | -545.4% | -323.6% | -105.9% | -73.1% | -27.7% | -59.9% | 44.8% | 390.5% | -70.1% | -63.2% | -48.9% | 73.3% | 87.8% |
| Valuation | |||||||||||||||
| P/B | — | — | 5.98 | 2.13 | 0.39 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| EPS Growth | 38.0% | 38.0% | 52.6% | 44.2% | — | -39.9% | — | — | — | — | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+129.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-10.00 → -6.20
Residual
+129.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.